Clinical Evaluation of Enteral-extended Anti-reflux Stents for Pancreatic Pseudocyst
Pancreatic Pseudocyst
About this trial
This is an interventional treatment trial for Pancreatic Pseudocyst
Eligibility Criteria
Inclusion Criteria: Pancreatic pseudocyst by a variety of causes, including acute pancreatitis, chronic pancreatitis, drug-induced pancreatitis Pseudocyst compressed gastrointestinal or bile duct and causes obstruction symptoms or causes other symptoms Diameter of pseudocyst >6 cm with no compression symptoms, but progressively increases and is failed to conservatively treat Exclusion Criteria: Wall-off necrosis with liquidation mimics pseudocyst Pseudocyst formation ≤8 weeks, cyst wall is immature Cannot puncture by EUS-guided approach for any reason Patients with serious cardiovascular or cerebrovascular diseases or other diseases which are not fitted to anaesthetize Severe coagulopathy or thrombocytopenia
Sites / Locations
- Peking University Third HospitalRecruiting
Arms of the Study
Arm 1
Arm 2
Experimental
Active Comparator
Enteral-extended Anti-reflux Stents Group
Traditional Stents Group
Patients are going to implant enteral-extended anti-reflux stents
Patients are going to implant traditional stents